CTI Clinical Trial and Consulting Services Opens Sao Paulo, Brazil Office
CTI Clinical Trial and Consulting Services announces that it has opened an office in S?o Paulo, Brazil
CTI Clinical Trial and Consulting Services (CTI), an international, privately held, full-service contract research organization announces that it has opened an office in São Paulo, Brazil. The office is opened through the wholly-owned subsidiary, CTI Clinical Brasil Serviços de Pesquisas Clínicas LTDA.
“We have been working on behalf of our pharmaceutical and biotechnology clients in the Latin America region for a number of years, and we believe that the region is one of the most important and fastest growing,” according to Patrick Earley, Vice President, International. “São Paulo, the largest city in Brazil and the largest city in the southern hemisphere, is key for our global expansion. Latin America’s immense population allows for a vast pool of potential trial patients and access to some of the top medical centers and universities in the world.”
With offices in North America, Europe, and South America, CTI has been working for over fifteen years in the drug development industry, specializing in clinical research programs involving critically ill patient populations.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
